Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Nov;59(6):632.
doi: 10.4103/0019-5154.143574.

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer

Ananaya Datta-Mitra  1 , Navdeep K Riar  2 , Siba P Raychaudhuri  1
Affiliations

Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer

Ananaya Datta-Mitra et al. Indian J Dermatol. 2014 Nov.

Erratum in

Abstract

Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), is employed for treatment of several cancers and retinopathies. Although previous reports of remission of psoriasis with bevacizumab do exist, but its current experience for psoriatic arthritis (PsA) is still limited. In this report, we describe a patient with metastatic renal cell cancer, psoriasis and PsA, who experienced a complete remission of psoriasis and PsA during bevacizumab therapy without any other management for psoriasis and PsA. We also found a flare up of his psoriatic disease after switching to other kinase inhibitors like sorafenib or sunitinib. This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.

Keywords: Angiogenesis; bevacizumab; psoriatic arthritis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Nil.

References

    1. Wilson JF. Angiogenesis therapy moves beyond cancer. Ann Intern Med. 2004;141:165–8. - PubMed
    1. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994;180:1141–6. - PMC - PubMed
    1. Young HS, Summers AM, Bhushan M, Brenchley PE, Griffiths CE. Single-nucleotide polymorphisms of vascular endothelial growth factor in psoriasis of early onset. J Invest Dermatol. 2004;122:209–15. - PubMed
    1. Gudbjornsson B, Christofferson R, Larsson A. Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis. Scand J Clin Lab Invest. 2004;64:9–15. - PubMed
    1. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999;141:1054–60. - PubMed